Clinical Research Directory

Inclusion Criteria: 1. Overweight or obese (BMI 27-45 kg/m2) 2. BCLC early to intermediate stage HCC 3. Referred for liver-directed therapy (PTA, TACE, TARE within 3 months) 4. English or Spanish speaking over the age of 18. 5. ECOG Performance Status ≤ 2. 6. Usual nightly fasting \<12 hours 7. Willing to comply with all study procedures 8. Child-Pugh A liver function. Exclusion Criteria: 1. Advanced HCC, progression, and/or associated comorbidities, metastatic disease, tumor in vein, or ascites 2. Advanced Cirrhosis (hypoalbuminemia/Child-Pugh B+C). Poorly controlled or refractory (grade 3-4) hepatic encephalopathy 3. Type 1 diabetes or self-reported hypoglycemia or hypoglycemic events by CGM 4. Participation in another conflicting study that requires modification of diet or food timing. 5. Uncontrollable eating pattern (e.g., wasting, Night Eating Syndrome, disordered eating habits, food insecurity) 6. Medications that markedly impact metabolic study biomarkers. 7. Other cancer in last 10 years (other than nonmelanoma skin cancer or carcinoma of the cervix in situ) 8. Serious medical conditions such as chronic kidney disease, congestive heart failure, or any condition that would interfere with participation in the trial. 9. Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy 10. Active alcohol abuse or less than 6 months of sobriety 11. Participation in a trial of an investigational agent within the prior 30 days 12. Pregnancy or lactating